Urinary biomarkers of exposure are used widely in biomonitoring studies. The commonly used urinary biomarkers for the aromatic solvents toluene (T), ethylbenzene (E), and m-xylene (X) are o-cresol, mandelic acid, and m-methylhippuric acid. The toxicokinetics of these biomarkers following inhalation exposure have yet to be described by physiologically based pharmacokinetic (PBPK) modeling. Five male volunteers were exposed for 6 h in an inhalation chamber to 1/8 or 1/4 of the time-weighted average exposure value (TWAEV) for each solvent: toluene, ethylbenzene, and m-xylene were quantified in blood and exhaled air and their corresponding urine biomarkers were measured in urine. Published PBPK model for parent compounds was used and simulations were compared with experimental blood and exhaled air concentration data. If discrepancies existed, Vmax and Km were optimized. Urinary excretion was modeled using parameters found in literature assuming simply stoichiometric yields from parent compound metabolism and first-order urinary excretion rate. Alternative models were also tested for (1) the possibility that CYP1A2 is the only enzyme implicated in o-cresol and (2) a 2-step model for describing serial metabolic steps for mandelic acid. Models adapted in this study for urinary excretion will be further used to interpret urinary biomarker kinetic data from mixed exposures of these solvents.
Determination of metabolites in urine is a common practice to assess exposure to volatile organic compounds. But those measurements are usually based on data for single exposure and do not consider possible interactions that may occur between coexposed chemicals. Although former studies on toluene, ethylbenzene, and m-xylene revealed no shifts in blood levels of parent compounds at low exposure levels during coexposures (Tardif et al., 1991 (Tardif et al., , 1995 , there is still a dearth of information regarding metabolic interaction impact on urinary metabolites.
Physiologically based pharmacokinetic (PBPK) modeling is a useful approach to study the possible mechanisms behind those interactions. Some studies have been conducted to investigate the effect of possible interactions between solvents on the levels of metabolites in urine (Elovaara et al., 1984; Engströ m et al., 1984; Tardif et al., 1997) but none has ever integrated those results to a PBPK model to simulate interactions at the urinary metabolites level. Previous studies investigating blood levels would only be representative of interactions occurring at the first step of metabolism because interactions occurring in subsequent steps would not modulate blood levels. Those results are useful to evaluate the real toxicity risk when parent compounds cause the toxic effects but urinary metabolites are more useful in a biomonitoring approach because of their accessibility.
A PBPK model for o-cresol excretion has been proposed by Tardif et al. (2002) . m-Xylene metabolite excretion has been studied (Engströ m et al., 1978; Riihimä ki, 1979; Riihimä ki and Hä nninen, 1987) but the resulting kinetic parameters (excretion rate and fraction of metabolism for each metabolite) have not been integrated to a PBPK model. Loizou et al. (1999) did use some of that information to model methylhippuric acid excretion. In the case of mandelic acid, no model or excretion rate could be found in literature.
Because our ultimate goal is to predict impact of coexposures on the kinetics of urinary metabolites used as biomarkers of exposures to toluene (T), ethylbenzene (E), and m-xylene (X), this study will focus on developing PBPK models for the metabolites of toluene, ethylbenzene, and m-xylene for single chemical exposures. The objective of the present study was therefore to collect human data from controlled inhalation exposures in order to refine existing PBPK models by integrating urinary excretion kinetics of their metabolites for single exposures and to validate these models. This study represents the first step in interpreting and modeling interactions occurring between common volatile organic compounds to predict their impact on their urinary level.
MATERIALS AND METHODS

Volunteer Exposures and Chemical Analyses
Material. Toluene (99.8% purity), ethylbenzene (99% purity), and m-xylene (!99% purity) were purchased from Sigma Aldrich. oCresol (!99% purity), m-methylhippuric acids (98% purity), mandelic acid (99% purity), hippuric acid (98% purity), o-cresold 8 , 2,3,4,5,6-pentafluorobenzyl bromide (99% purity), tetrabutylammonium (TBA) hydrogensulphate, methanol (!99% purity), dichloromethane (!99% purity), sodium hydroxide (1 M), sulfuric acid (0.5 M), and NaH 2 PO 4 ÁH 2 O were purchased from Sigma Aldrich. 3, 4, 5, 5 acid was purchased from CDN Isotope Inc (Pointe-Claire, Canada). Toluene-13 C 6 , ethylbenzene-13 C 6 and m-xylene-13 C 2 were purchased from Cambridge Isotope Laboratories Inc (Andover, Massachusetts).
Volunteers. Five male volunteers aged between 18 and 35 years and weighting between 58 and 100 kg participated in this study. They were non-smokers with no recent history of exposure to high levels of VOCs or health issues (assessed by a questionnaire). They were asked not to consume alcohol for a 24-h period before and after exposures. They provided their informed consent and the project was approved by the ethical committee of Université de Montré al and Health Canada.
Exposure chamber. The human exposure chamber system located in the Inhalation Laboratory of the Department of Environmental and Occupational Health of the Université de Montré al has previously been described by Tardif et al. (1991) . Solvent concentrations in air were generated by introducing with an HPLC pump (Varian 2510) the solvents in a roundbottom flask and mixing them with a stream of purified air. This air then passed through 16 diffusers in the chamber ceiling. Concentrations in the chamber air were monitored every 10 min by directly sampling the air from the chamber with a pump connected to a gas chromatograph. Concentrations were also continuously monitored by a Miran205B Series SapphIRe infrared spectrophotometer (CD Nova Ltd, Burnaby, British Columbia, Canada). Mean variation of concentrations in chamber during each experiment was 5%.
Exposures. Volunteers were exposed to one-fourth and one-eight of the time-weighted average exposure value (TWAEV) (Government of Quebec, 2014) of each solvent. They were exposed for 6 h/day with 1-week interval between each day of exposure. TWAEVs are 50 ppm for toluene and 100 ppm for ethylbenzene and m-xylene.
Exhaled air samples were collected throughout the exposure time (time points: 0, 1.5, 3, 4.5, 6, 6.5, and 7 h) in 3 l Tedlar bags. One blood sample was collected 5 min before exposure to measure background exposure and subsequent samples were collected after the end of exposure (15, 45, 90 , and 120 min after the end of exposure). A catheter was installed to facilitate sampling. Samples were then kept refrigerated until analysis. Urinary void was collected immediately before exposure. During the 24 h following start of exposure, all urines were collected to obtain composite urine for 4 different time intervals (0-3.5, 3.5-8, 8-15, and 15-24 h) . A total of 5 samples per volunteer were stored at À20
C for further analysis.
Analytical Methods
Parent compound analyses in exhaled and chamber air. Concentrations in chamber and exhaled air samples were analyzed for parent compounds by gas chromatography as previously described (Tardif et al., 1991) . Briefly, air from chamber and Tedlar bags was routed by a pump to an automatic injection system for volatile compounds including an electric valve and a pneumatic injection loop (1 ml vol) which was coupled to a Varian CP-3800 gas chromatograph. The column used was an HP1 (30 m Â 0.53 mm, 1.0 mm film thickness) (Agilent Tech, Canada). Toluene, ethylbenzene, and m-xylene were analyzed through a flame ionization detector.
Parent compound analyses in blood. Blood samples were analyzed by modified method described by Blount et al. (2006) consisting of isotope dilution solid phase microextraction gas chromatography tandem mass spectrometry (SPME-GC-MS/MS). The analytical instrument was a TRACE Ultra Gas Chromatograph-TSQ quantum XLS mass spectrometer (ThermoFisher Scientific, Massachusetts). The column used was DB-VRX capillary column (0.18 mm Â 40 m, 1.0 mm film thickness) (J&W Scientific, Folsom, California). Briefly 0.5 g of blood were transferred to a preweighed SPME headspace vial using a 3-ml precleaned glass syringe and 30.0 ml of internal standard solution were added, the vial was crimped shut and mixed thoroughly. Samples were queued in the Combi-PAL (Varian, Palto Alto, California) vial tray, cooled to 15 6 0.5 C until analysis.
The analytical instrument was a TRACE Ultra Gas Chromatograph-TSQ quantum XLS mass spectrometer (ThermoFisher Scientific). A Cryotrap 915 (ThermoFisher Scientific, Milan, Italy) was used to cryo-focus analytes using approximately 11 cm of base deactivated-guard column (Restek, Chromatographic Specialties, Brockville, Ontario). The column used was DB-VRX capillary column (0.18 mm Â 40 m, 1.0 mm film thickness) (J&W Scientific).
During analysis, each sample was transferred to the conditioning/agitator station, held at 40 C. The SPME fiber (75 -mm
Carboxen-PDMS coated, Supelco, Bellefonte, Pennsylvania) was MARCHAND ET AL. | 415 inserted into the sample headspace for 6 min while the vial was agitated at 500 rpm. The SPME fiber was then immediately transferred to the GC injection port held at 220 C, and held for a 30-s desorption time. After injection the cryotrap was maintained at À140 C for 1.5 min, and then heated ballistically to 225 C to desorb analytes from the precolumn. The analytical column was maintained at an initial oven temperature of 0 C to further focus the volatile analyte band. The GC oven was held at 0 C for 1.5 min, ramped at 14 C/min to 145 C and finally ramped at 7 C/min to 160 C for a total chromatographic time of 14 min.
The carrier gas flow was maintained at a constant rate of 1 ml/min. The detector was a TSQ Quantum XLS Mass spectrometer equipped with an electron ionization source. The source temperature was 180 C, and transfer line temperature was 160 C. The MS was operated in selected reaction monitoring mode, with Q1 and Q3 peak width set at 0.7 (FWHM) and a cycle time of 0.2 s.
Urinary metabolite analyses. Urine samples were thawed on ice; 1 ml of sample were hydrolyzed with 2 M H 2 SO 4 and heating at 100 C for 30 min followed by an extractive alkylation as described by Marais and Laurens (2005) with some modifications to optimize the extraction. TBA solution concentration was increased to 0.4 M and sodium phosphate buffer (monoand dibasic) was adjusted to a pH of 10.5. Derivatized samples were analyzed by an Agilent 7890A series GC coupled to a an Agilent 7000 triple quadrupole (MS/MS) mass spectrometer (Agilent Technologies, Palo Alto, California) and a CTCCombiPal automatic injector (CTC, Switzerland). Inlet temperature was increased to 300 C to allow better volatilization of derivatized metabolites. A DB-1MS fused-silica capillary column (30 m Â 250 mm, 0.1 mm film thickness) (Agilent Technologies) was used with helium as gas carrier at a flow rate of 1.3 ml/min. Analysis parameters for MS transitions are presented in Table 1 .
PBPK MODELING OF PARENT COMPOUNDS AND METABOLITES
Model Representation Parent compound. PBPK model for each chemical is represented as a tissue network composed of richly perfused tissues, slowly perfused tissues, adipose tissues, and liver ( Fig. 1 ). These 4 compartments are interconnected by systemic circulation and gas exchange in the lung. Metabolism is limited to the liver and is described by Vmax (mg/h) and Km (mg/l). All kinetics (except for metabolites excretion) are described by Ramsey and Anderson (1984) equations.
Urinary biomarkers. In Figure 2A , metabolism for each monitored metabolite is represented. o-Cresol is first represented as a fraction of the toluene metabolism by CYP2E1 (CYP2E1 model) (Tardif et al., 2002) . Amount of o-cresol in urine is therefore described by a stoichiometric yield (SY) and an excretion constant (K CRE ). On the other hand, literature suggests that o-cresol is formed by CYP1A2 activity (Kim et al., 1997; Nakajima et al., 1997; Tassaneeyakul et al., 1996) . An alternate description ( Fig. 2B ) for o-cresol was therefore suggested (CYP1A2 model) by using a first-order metabolic rate constant (K TOL ) for its formation by CYP1A2 and a first-order rate constant for its urinary excretion (K CRE ).
A first model (1-step model) was proposed to describe mandelic acid excretion with a SY parameter and a first-order excretion rate constant (K MA ) (Fig. 2C) . Because literature mentions the existence of a rate limiting step , a second representation for mandelic acid formation and excretion (Fig. 2D ) is proposed (2-step model) and is composed of 2 different steps. The first step is the conversion of ethylbenzene to mandelic acid which can be converted to phenylglyoxylic acid (second step) or excreted in urine with a first-order rate constant (K MA ). The first step is described as a saturable process with Vmax and Km values and the second step as a first-order rate constant. Finally, the model for m-methylhippuric acid (Fig. 2E ) is described by a SY component followed by a first-order excretion rate constant (K MHA ).
Model Parameterization Parent compound. Physiological parameters (Table 2) for all 3 compounds were the same and values were taken from Tardif et al. (1997) . Because Km and Vmax values from Tardif et al. (1997) and those from Haddad et al. (1999) were different for toluene and m-xylene, they were both tested with our data (Table 3) .
Urinary excretion. For o-cresol, a SY of 0.0078 (% of metabolism that yields to the metabolite formation) and excretion rate 0.715 h À1 kg À1 were taken from the PBPK model of Tardif et al. (2002) (Table 4) . A first-order constant was also used to simulate o-cresol formation by CYP1A2. The SY of 0.97 for m-methylhippuric acid is the one reported by Engströ m et al. (1984) and the excretion rate of 1.3 h À1 was taken from Riihimä ki (1979).
Parameters for mandelic acid excretion in urine were estimated in this study except for SY for mandelic acid and phenylglyoxylic acid (0.9) and for mandelic acid alone (0.7) which were taken from Engströ m et al. (1984) . ethylbenzene and m-xylene). Excretion parameter values described above were incorporated into the models (Table 4) . The different mass balance differential equations representing the toxicokinetics of parent compounds and their metabolites were written as a program and solved with ACSLXtreme software (Aegis Technologies Inc, Huntsville, Alabama). Optimizations were performed using ACSLX Optimum. Heteroscedasticity parameters were kept at 1 and the NelderMead algorithm was used. When more than 1 model is proposed, Nelder-Mead optimization is performed on all models and then the best visual fit was used to determine which model should be retained.
Model Calibration and Simulations
Parent compound. As a first step, simulations for parent compound kinetics in blood and air, using parameters values in Table 3 , were compared with data obtained experimentally to determine whether metabolic constants were appropriate to describe the data. In the case where predictions were off of experimental data range, optimization of these parameters was performed. Km values were not optimized. Optimization was made by fitting model to experimental data for venous blood and exhaled air.
Urinary excretion. Data for urinary biomarkers were compared with model predictions. If parameters for excretion could not predict the experimental results in urine, they were optimized. When optimization was unable to provide good fit, alternative models with intermediate steps for metabolism were used for simulation and optimization as mentioned above (Figs. 2B and 2D).
RESULTS
Experimental data for single exposure were compared with simulations from existing models (Haddad et al., 1999; Tardif et al., 1997) and kinetic parameters for the urinary excretion of the metabolites were subsequently added and adjusted to experimental data. The model of Tardif et al. (1997) overpredicted the experimental data for toluene concentration in blood while the Km and Vmax values from Haddad et al. (1999) model provided a better fit with the experimental data (Fig. 3) . Blood concentrations of ethylbenzene were also overestimated by the model of Tardif et al. (1997) . Since data for ethylbenzene in blood tended to be lower than simulations and no other in vivo values for Vmax or Km were available in the literature, Vmax was optimized (Table 4 ). The new Vmax for ethylbenzene is around 50% higher (13.32) than the values reported in other in vivo studies (7.3) (Tardif et al., 1997; Haddad et al., 1999) . m-Xylene blood levels were well predicted by the Tardif model.
For toluene concentration in exhaled air (Fig. 4) , data obtained during inhalation are well predicted by Tardif's model but post-exposure data are overestimated. Replacement of Km and Vmax values for those from Haddad et al. (1999) fitted the experimental data better. The change in Vmax   FIG. 2 . Conceptual representation of (A) o-cresol formation by CYP2E1, (B) o-cresol formation by CYP1A2, (C) single step mandelic acid formation, (D) mandelic acid formation with a rate limiting step and formation of phenylglyoxylic acid from mandelic acid, and (E) formation of m-methylhippuric acid. SY refers to the stoichiometric yield (% of total metabolites) and K OCR , K MA , and K MHA are excretion constants for o-cresol, mandelic acid, and m-methylhippuric acid (MHA), respectively. KTOL is a first-order constant for o-cresol formation by CYP1A2. Vmax, Km, and Cvl are the maximal velocity of the metabolism, the affinity constant, and venous concentration for liver, respectively. , 2015, Vol. 144, No. 2 (optimization) for ethylbenzene did not alter the capacity of the model to predict experimental data. In the case of m-xylene, if blood concentrations could be well predicted at both levels of exposure, only data for the exposure at one-eighth of the TWAEV were close to model predictions in exhaled air.
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All models for o-cresol excretion could adequately predict our results (Fig. 5) . Simulations for o-cresol formation occurring via CYP1A2 and the simulations for CYP2E1 with an optimized SY provided a similar fit with experimental data. Original and optimized parameter values are given in Table 4 .
Mandelic acid excretion in urine was slower than ethylbenzene elimination from blood. When using the 1-step model, simulations could not follow the curve suggested by measured levels of mandelic acid in volunteers, nor be optimized to do so. When using the 2-step model with formation of PGA from mandelic acid, an adequate optimization could be achieved to simulate the mandelic acid excretion data. Original and optimized parameter values are presented in Table 4 .
In the case of m-methylhippuric acid (MHA) excretion, using the reported SY (0.97) and urinary excretion constant (1.3 h À1 ) for MHA, the model accurately predicted the observed results (Fig. 5) .
DISCUSSION
The main objective of this study was to extend the existing PBPK models for toluene, ethylbenzene, and m-xylene to incorporate a description of the excretion kinetic of their urinary biomarker with results for single exposures. Predictions from existing models were first compared with experimental data for blood and alveolar air. An excretion constant and a SY for each biomarker were then added to validated models in order to predict urinary excretion levels of these biomakers. When metabolite excretion could not be predicted properly, alternative models were investigated.
MODEL PREDICTIONS VERSUS EXPERIMENTAL DATA FOR PARENT COMPOUNDS IN BLOOD AND ALVEOLAR AIR
The high level of exposure (one-fourth TWAEV) in our study is relatively close to the exposure level published in Tardif et al. (1997) (ie, 12.5 ppm vs 17 ppm, respectively, for toluene and 25 ppm vs 33 ppm for ethylbenzene and m-xylene). No similar time points were used in both studies except for measurement Baelum et al. (1985) . of air concentrations. Experimental data can however be compared with predictions from Tardif et al. (1997) model. Tardif's model did not properly predict experimental data in this study for toluene concentration in blood but did predict adequately exhaled air concentrations during exposure, postexposure data being overestimated. Because of these discrepancies, Vmax and Km values from Haddad et al. (1999) were then tested. They were more accurate for toluene levels in exhaled air (post exposure data) and blood (Figs. 3 and 4) compared with Tardif's model and were kept for urinary excretion of o-cresol modeling. Vmax and Km values from Haddad et al. (1999) are based on a rat study just like those from Tardif for toluene (Tardif et al., 1995) . The fact that Tardif et al. (1997) had 2 time points during the exposure compared with Haddad et al. (1999) and this study where all samples were collected after end of exposure could have contributed to the difference observed in Vmax and Km values between studies.
Exhaled air result after 6 h of inhalation for the exposure to ethylbenzene is equal to 72% of that from Tardif et al. (1997) which nicely reflects the 75% difference in exposure levels in both studies. However, using Tardif values for Vmax and Km, the PBPK model overestimated venous blood concentrations for ethylbenzene (Fig. 3) . Therefore, new values were optimized as no other published in vivo values with a higher intrinsic   FIG. 3 . Comparisons of PBPK model simulations (lines) and experimental data (h) of blood concentrations of toluene, ethylbenzene, and m-xylene in human volunteers exposed to one-fourth or one-eighth of the TWAEV by inhalation for 6 h. Simulations were run with existing models (dotted lines) and with optimized parameters (solid lines). In the case of toluene, the dotted line is for model from Tardif et al. (1997) and the solid line is for Haddad et al. (1999) model. Each data point represents the mean (6SD) of 5 volunteers.
clearance existed for humans. Km was kept unchanged because optimization of both parameters simultaneously always gave the same Vmax/Km ratio regardless of their values, thus suggesting the absence of saturation at these exposure levels. A Vmax value of 13.32 mg/h/kg was obtained. Interestingly, after conversion according to Lipscomb et al. (2004) reported in vitro values by Sams et al. (2004) would give a Vmax of 8.5 mg/h/kg with a Km of 0.85 mg/l. The Vmax/Km ratio of 10 is very close to the one obtained with optimized value of 13.32 mg/h/kg for Vmax and a Km of 1.39 mg/l. Even if the model for m-xylene accurately predicted parent compound concentrations in blood samples, it had mixed success in alveolar air (ie, good prediction at one-eighth TWAEV but slight underprediction at one-fourth TWAEV). Although subject in this study where exposed at 25 ppm of m-xylene compared with 33 ppm for Tardif, values for exhaled air concentration obtained at 6 h after beginning of exposure were very similar (4.7 ppm vs 4.5 ppm in this study). A 25% difference would have been expected, and this is confirmed by the mean 22% difference between experimental data and model predictions. unteers exposed by inhalation to one-fourth or one-eighth of the TWAEV for 6 h. Simulations were run with existing models (dotted lines) and with optimized parameters (solid lines). In the case of toluene, the dotted line is for model from Tardif et al. (1997) and the solid line is for Haddad et al. (1999) model. Each data point represents the mean (6SD) of 5 volunteers.
MODEL PREDICTIONS VERSUS EXPERIMENTAL DATA FOR URINARY BIOMARKERS
Modeling o-cresol excretion in urine using parameters for CYP2E1 activity (Vmax and Km values), a SY and published excretion constant (Tardif et al., 2002) permitted a good fit with experimental data in urine for this study as well as for Tardif et al. study (Fig. 6) . However, the SY was optimized to achieve a better fit (Table 4) . The other possibility suggests CYP1A2 would be responsible for the aromatic hydroxylation producing o-cresol such as demonstrated in in vitro studies (Kim et al., 1997; Nakajima et al., 1997; Tassaneeyakul et al., 1996) . Following that idea and because saturation of that enzyme is unlikely to occur at levels of exposure in our study, we attempted to describe o-cresol formation by a first-order constant. A value of 0.122 h À1 kg À1 was obtained and provided a good correlation with our data. This alternative model could be useful in interpreting possible interactions between coexposed chemicals. , 2015, Vol. 144, No. 2 In terms of modeling, results for mandelic acid excretion did not fit very well the predictions using only a SY and an excretion constant (Fig. 5) . One plausible explanation could be that there are some intermediate limiting steps that modulate the excretion rate. Conversion of ethylbenzene to 1-phenylethanol is supposed to occur at a similar rate than m-xylene metabolism while subsequent steps would be much slower, thus limiting metabolite excretion rates . Another important aspect is that phenylglyoxylic acid is thought to be formed by ADH enzyme from mandelic acid . As shown in Figure 5 , the addition of that step is needed to provide a good fit of our data to the urinary excretion curves of mandelic acid.
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The model adapted in this study was compared with experimental data (Fig. 6 ) from a former study (Tardif et al., 1997) . Although predictions for blood levels for toluene were a little low near the end of exposure, the model did provide good fit for other data. All experimental data for alveolar air concentration were well predicted by the model. Only the last data for o-cresol cumulative urinary excretion could be predicted by the model. This could be due to differences in analytical method used for measuring small concentrations of metabolite in urine, since a more accurate method was used in this study. First data points for mandelic acid excretion were relatively well predicted while the 24 h amount was underpredicted at 40%. When considering the theoretical amount of ethylbenzene metabolized, mandelic acid is expected to represent around 55% of total metabolites and between 35% and 65% of total mandelic acid was expected to be excreted after 24 h (Gromiec and Piotrowski, 1984) . In our study, an amount between 50 and 93 mg of mandelic acid after 24 h was expected (exposure at one-fourth TWAEV). The expected amount excreted in Tardif's study is between 80 and 148 m, and observed results fall on the upper end of this range whereas simulations fall on the lower end. The difference between our simulation and observed value which is less than 2-fold can therefore be attributed to variability between the two sets of participants. In the case of cumulative m-methylhippuric acid excreted in Tardif's study, our model overpredicted the results of 8 and 24 h by a factor of less than 2-fold, although the shape of the curve is similar. Here again, the differences may be due to interindividual differences or methodological differences in metabolite measurement. However, reported parameters in literature for urinary excretion of m-methylhippuric acid allowed a good fit of our data with model predictions.
Most biomonitoring studies use spot urine samples rather than cumulative (eg, 24 h) samples. Although spot sample may be logistically simpler, they often lead to over-or underpredictions comparatively to cumulative excreted amounts (Fortin et al., 2008; Gupta et al., 2014) . In this study, cumulative excreted amounts were shown to have a much lower variability than using concentrations adjusted by creatinine (not shown). Because ultimate goal of this study is to use model in biomonitoring to estimate COV exposure levels, it is suggested that, in the context of quantitative exposure assessments, urine sampling be performed to cover a defined period of time to determine cumulative excreted amounts. FIG. 6 . Comparisons of PBPK model simulations (lines) and experimental data (h) for cumulative excreted metabolites from Tardif et al. (1997) . Each data point represents the mean (6SD) of 4 volunteers. Exposure concentrations for toluene, ethylbenzene, and m-xylene are 17, 33, and 33 ppm, respectively, for 7 h.
In conclusion, models developed in this study can appropriately predict urinary biomarkers for low level exposures to toluene, ethylbenzene, and m-xylene. If models adjusted for urinary metabolite excretion in this study can predict human data for single exposure they still have to be tested with data from exposure to chemical mixture. Further efforts are currently ongoing to validate these models in the context of exposure to mixtures. They could be used for the interpretation of large scale exposure biomonitoring studies such as the Canadian Health Measures Survey (CHMS).
